The Claim
Selenium supplementation does not consistently improve remission rates following antithyroid drug treatment in patients with Graves' disease, as no significant difference in relapse rates is observed between selenium and placebo groups, and serum selenium levels are not correlated with remission outcomes.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking selenium supplements after standard treatment for Graves' disease does not reliably lead to better long-term remission, and blood levels of selenium do not predict whether the disease will return.
See the scientific wording
Selenium supplementation does not consistently improve remission rates after antithyroid drug treatment in Graves' disease, as conflicting results from small trials show no significant difference in relapse rates between selenium and placebo groups, and serum selenium levels do not correlate with remission outcomes.
What the research says
1 studyStudy: Challenges and perspectives of selenium supplementation in Graves’ disease and orbitopathy
This study says we don’t have clear proof that selenium pills help people with Graves’ disease stay healthy after stopping their main medicine — some small studies say yes, others say no, so we just don’t know for sure.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.